Baicalin and lung diseases

Studies focusing on natural products have been conducted worldwide, and the results suggest that their natural ingredients effectively treat a wide range of illnesses. Baicalin (BIA) is a glycoside derived from the flavonoid baicalein present in Scutellaria baicalensis of the Lamiaceae family. Inter...

Full description

Saved in:
Bibliographic Details
Published in:Naunyn-Schmiedeberg's archives of pharmacology 2024-03, Vol.397 (3), p.1405-1419
Main Authors: Sharawi, Zeina W., Ibrahim, Islam M., Abd-alhameed, Esraa K., Althagafy, Hanan S., Jaber, Fatima A., Harakeh, Steve, Hassanein, Emad H. M.
Format: Article
Language:English
Subjects:
1-Phosphatidylinositol 3-kinase
AKT protein
Animal models
Antitumor activity
Apoptosis
Baicalin
Biomedical and Life Sciences
Biomedicine
Chronic obstructive pulmonary disease
Embolism
Fibrosis
Flavonoids
Immune response
Lung cancer
Lung diseases
Natural products
Neurosciences
NF-κB protein
Oxidative stress
Paraquat
Pharmacology/Toxicology
Review
Stat3 protein
TLR4 protein
Toll-like receptors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Studies focusing on natural products have been conducted worldwide, and the results suggest that their natural ingredients effectively treat a wide range of illnesses. Baicalin (BIA) is a glycoside derived from the flavonoid baicalein present in Scutellaria baicalensis of the Lamiaceae family. Interestingly, BIA has been shown to protect the lungs in several animal models used in numerous studies. Therefore, we fully analyzed the data of the studies that focused on BIA’s lung protective function against various injuries and included them in this review. Interestingly, BIA exhibits promising effects against acute lung injury, lung fibrosis, pulmonary embolism, and lung remodelling associated with COPD, LPS, and paraquat insecticide. BAI exhibits anticancer activity against lung cancer. Additionally, BIA potently attenuates lung damage associated with infections. BIA primarily exerts its therapeutic effects by suppressing inflammation, oxidative stress immune response, and apoptosis pathways. Nrf2/HO-1, PI3K/Akt, NF-κB, STAT3, MAPKs, TLR4, and NLRP3 are important targets in the pulmonary therapeutic effects of BIA on different lung disease models. Consequently, we recommend using it in future potential clinical applications, its contribution to treatment guidelines, and translating its promising effects to clinical practice in lung diseases. Graphical Abstract
ISSN:0028-1298
1432-1912
DOI:10.1007/s00210-023-02704-1